CN106107979A - 一种具有抗衰老功能的保健品 - Google Patents
一种具有抗衰老功能的保健品 Download PDFInfo
- Publication number
- CN106107979A CN106107979A CN201610485583.0A CN201610485583A CN106107979A CN 106107979 A CN106107979 A CN 106107979A CN 201610485583 A CN201610485583 A CN 201610485583A CN 106107979 A CN106107979 A CN 106107979A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- group
- product
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 241000628997 Flos Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 14
- 229940046009 vitamin E Drugs 0.000 claims abstract description 14
- 239000011709 vitamin E Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000032683 aging Effects 0.000 abstract description 15
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000000047 product Substances 0.000 description 26
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 229960003180 glutathione Drugs 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- 235000003969 glutathione Nutrition 0.000 description 5
- 238000005065 mining Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 206010006179 Breast atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241001459693 Dipterocarpus zeylanicus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白300‑500份、维生素C 80‑150份、维生素E 10‑40份、玫瑰花提取物8‑16份。该保健品配方科学合理，食用方便，产品营养充分，各组分协同作用促进机体对养分的吸收，可显著提高机体抗氧化和抗衰老能力，提高免疫力，减少机体因衰老引发的各种疾病的风险，增强机体抵抗力。此外，本发明产品安全，无毒副作用，对延缓衰老具有切实的保健效果。
Description
技术领域
本发明涉及了一种保健产品，具体涉及一种具有抗衰老功能的保健品。
背景技术
衰老是一种自然的过程，是生物与外在环境长期相互作用的结果，随着年龄的增长，人类身体机能开始下降，表现为结构和机能衰退，适应性和抵抗力减退。衰老较为明显的表征有：钙质流失引发的骨质疏松，血管硬化引发心脑血管疾病、中风，免疫功能下降、性功能下降等。据有关资料统计，近年来，40岁左右的中年人患心肌梗死、脑出血等心脑血管疾病的大幅上升，而且冠心病、高血压、高血脂、糖尿病等疾病的发病率也趋于年轻化。其原因主要是：中青年人在工作和生活的双重压力下，过度消耗与透支体能，使组织器官提前衰老。随着人们生活水平的提高，人们不断寻求可以健康长寿，提高免疫力，战胜各种疾病，提高身体机能的方法，以提高生活质量。因此需要不断开发具有抗衰功能的药食同源的容易被人体吸收和利用的营养保健食品成为本领域技术人员急需解决的技术问题。
发明内容
本发明的目的在于提供一种具有抗衰老功能的保健品。该保健品配方科学合理，易于人体吸收，能够显著改善机体衰老状态，从而达到增强免疫力战胜各种疾病的目标。
本发明采用以下技术方案：
一种具有抗衰老功能的保健品，其特征在于，它是由以下重量份的原料组成：胶原蛋白300-500份、维生素C 80-150份、维生素E 10-40份、玫瑰花提取物8-16份。
优选的，所述的抗衰老功能的保健品，其特征在于，它是由以下重量份的原料组成：胶原蛋白400份、维生素C 100份、维生素E 20份、玫瑰花提取物10份。
优选的，所述的抗衰老功能的保健品，所述各原料按量称取后，按照常规方法制成胶囊剂、片剂、颗粒剂、粉剂或丸剂。
本发明是以胶原蛋白、维生素C、维生素E、玫瑰花提取物为主要原料的保健品。胶原蛋白，是细胞外基质的主要成分，是哺乳动物体内含量丰富的蛋白质，其广泛存在于皮肤、骨、肌腱、牙齿、韧带、软骨和血管中，起着支撑器官和保护机体的重要功能。由于其含有相容性，保水性、吸水性和抗衰老性，所以广泛被应用于食品保健品与化妆品中。维生素C是胶原蛋白合成中必不可少的物质。在前胶原蛋白的前α-肽链形成过程中，部分羟脯氨酸及羟赖氨酸需经内质网中脯氨酰羟化酶及赖氨酰羟化酶催化，在此羟化的过程中维生素C可以激活此类酶，使得羟脯氨酸及羟赖氨酸形成羟脯酰胺及羟赖酰胺残基。而失去维生素C使得胶原蛋白受阻，产生结缔组织弹性降低导致坏血病等症状。并且，有文献证明，胶原蛋白的浓度若高于1％，皮肤就无法正常吸收。而添加抗坏血酸确实有促进皮肤组织对于胶原蛋白的吸收与增生效果。说明，维生素C可以有效促进胶原蛋白的吸收。并且，维生素C是有效的抗氧化物质，这也可以说明本发明保健品可能有抗氧化抗衰老的能力。维生素E是一种抗氧化的物质，同时，文献报道，补硒补维生素E后，能缓解心肌细胞对诱发因素所造成的损伤，对保护心肌细胞和防止心肌纤维化的形成具有一定作用。表明了维生素E与胶原蛋白也有一定的关系。玫瑰花具有理气解郁，化湿和中，活血散瘀的功效。此外，玫瑰花还含有多种营养成分，对某些皮肤病有很好的疗效，长期使用能彻底去除痤疮和粉刺，使面部的皮肤光滑柔嫩，对治疗面部黄褐斑有一定作用。为了证明本发明保健品的抗氧化和抗衰老功效，我们设计了以下实验。本实验主要是以小鼠的血清中过氧化物歧化酶、谷胱甘肽过氧化酶的活性及丙二醛与抗氧化物还原型谷胱甘肽的含量为指标，考察胶原蛋白粉的抗衰老能力。
实验材料及设备：受试样品为本发明制备的保健品。多功能酶标仪(synergybiotech)，离心机(Thermo)。T-SOD测试盒(100T/96样，南京建成)，丙二醛测试盒(100T/96样，南京建成)，谷胱甘肽过氧化酶测试盒(100T/48样，南京建成)，微量还原型谷胱甘肽测试盒(96T，南京建成)。
实验方法：将70只20-25g 3月龄雄性昆明小鼠随机分组，分别为空白对照组、模型组、治疗组、玫瑰提取物对照组、胶原蛋白对照组，其中治疗组中又分为低剂量组，中剂量组，高剂量组，每组10只，分笼饲养，自由饮水饮食。其中，除空白对照组外，其余六组腹腔注射混合液体0.1ml/10g/day(指含有不同种类和剂量治疗和预防药物的液体)，均含D-半乳糖0.04mg。玫瑰花提取物组除注射D-半乳糖外，以0.2mg/10g/day(与治疗组高剂量组的日用量相等)灌胃给予本发明所用玫瑰花提取物；胶原蛋白组除注射D-半乳糖外，以7.5mg/10g/day(与治疗组高剂量组的日用量相等)灌胃给予本发明所用胶原蛋白粉；治疗组除注射D-半乳糖外，低剂量组以2mg/10g/day灌胃本发明受试样品，中剂量组以5mg/10g/day灌胃，高剂量组以10mg/10g/day灌胃，D-半乳糖模型组灌胃相同量的水，连续持续42天，取材前12小时断食。取小鼠眼眶血，静置1小时后，离心(3000r/min，15min/)取上清冷冻备用。分别对小鼠的超氧化物歧化酶(T-SOD)活力、丙二醛(MDA)含量、谷胱甘肽过氧化物酶(GSH-XP)活力、还原型谷胱甘肽(GSH)含量进行测定。
实验结果：
1、本发明产品对衰老模型小鼠血清超氧化物歧化酶(T-SOD)活力的影响
表1小鼠血清超氧化物歧化酶(T-SOD)含量结果
注：*代表与衰老模型对照组对比p<0.05，***代表p<0.001。
#代表与空白对照组相比p<0.05，###代表p<0.001。
从上表中的数据可以看出，低、中剂量组与衰老模型组相比，小鼠血清超氧化物歧化酶(T-SOD)含量均有明显上升，p<0.001表明低剂量和中剂量组SOD含量比衰老组有明显改善。高剂量组与衰老模型对照组相比有下降趋势，且有显著性差异，p值<0.05。与空白对照组分别相比，低、中剂量组显著升高，p值均<0.001，差异极显著。
2、对衰老模型小鼠血清丙二醛(MDA)含量的影响
表2血清样本中MDA含量的测定结果
注：*代表与衰老模型组相比p<0.05；#代表与空白对照组相比p<0.05。
由表2可知，与空白对照组相比，用D-半乳糖造模的模型对照组能够明显提高MDA含量，治疗组低剂量对于降低MDA效果甚微，而中、高剂量组均能够明显降低MDA的水平，且具有统计学意义，p值均<0.05。与衰老模型对照组相比，玫瑰花提取物组和胶原蛋白组均对MDA的降低有一定影响，但没有显著性差异。
3、对衰老模型小鼠血清谷胱甘肽过氧化物酶(GSH-XP)活力的影响
表3血清样本中GSH-PX酶活力测定结果
注：*代表与衰老模型组相比p<0.05，***代表p<0.001；###代表与空白对照组相比p<0.001。
由表3可知，与空白对照组相比，衰老模型组GSH-PX酶活力显著减低，p<0.001。低剂量组对GSH-PX酶活力影响不明显，中剂量和高剂量治疗组能够显著提高血清GSH-PX酶活力水平，差异显著，p<0.001。并接近或略微超过正常空白对照组水平。这说明使用本发明中、高剂量的保健品能够有效缓解衰老模型小鼠血清GSH-PX酶活力下降。而对于玫瑰花提取物组和胶原蛋白组，与模型对照组相比，玫瑰花提取物组对小鼠血清GSH-PX酶活力的提高比较小，而胶原蛋白组对小鼠血清GSH-PX酶活力的提高相对较明显，但与本发明产品相比，二者对小鼠血清GSH-PX酶活力的提高的总和也不如本发明产品的中、高剂量治疗组的效果好。
4、对衰老模型小鼠血清还原型谷胱甘肽(GSH)含量的影响
表4血清样本中微量还原型谷胱甘肽的测定结果
注：*代表与模型组相比p<0.05，#代表与空白组相比p<0.05。
由表4可见，衰老模型组与空白对照组相比，血清GSH含量明显降低。治疗组中不管是低剂量、中剂量还是高剂量组与模型组相比，GSH含量均有显著升高，p值<0.05。而与模型对照组相比，玫瑰花提取物组与胶原蛋白组对GSH含量的提高均幅度较小，二者的增幅之和还小于治疗组中任一剂量的增幅。这可能是由于本发明配方中各组分的协同增效作用，各组分虽然单独也会对机体的GSH含量有一定程度的提高，但是按照本发明配方比例混合后，各组分协同增效，促进机体对各养分的吸收，增强机体的抗氧化和抗衰老能力。
本发明的有益效果是：本发明的保健品配方科学合理，食用方便，产品营养充分，各组分协同作用促进机体对养分的吸收，可显著提高机体抗氧化和抗衰老能力，提高免疫力，减少机体因衰老引发的各种疾病的风险，增强机体抵抗力。此外，本发明产品安全，无毒副作用，对延缓衰老具有切实的保健效果。
具体实施方式
下面结合具体实施例对本发明做进一步的详细说明。
实施例1
一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白300份、维生素C 80份、维生素E 10份、玫瑰花提取物8份。
所述各原料按量称取后，按照常规方法制成胶囊剂，0.5g/粒。
实施例2
一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白500份、维生素C 150份、维生素E 40份、玫瑰花提取物16份。
所述各原料按量称取后，按照常规方法制成片剂，0.4g/片。
实施例3
一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白400份、维生素C 100份、维生素E 20份、玫瑰花提取物10份。
所述各原料按量称取后，按照常规方法制成颗粒剂，1g/袋。
实施例4
一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白350份、维生素C 110份、维生素E30份、玫瑰花提取物12份。
所述各原料按量称取后，按照常规方法制成粉剂，1g/袋。
实施例5
一种具有抗衰老功能的保健品，它是由以下重量份的原料组成：胶原蛋白450份、维生素C 120份、维生素E 35份、玫瑰花提取物10份。
所述各原料按量称取后，按照常规方法制成丸剂，0.5g/丸。
本发明的具有抗衰老功能的保健品经过长期临床验证，均取得不同程度的良好的疗效，临床治疗过程中所有患者均无任何不适症状。
例1：跟踪100例患者，此100例患者，免疫力低，天气稍有变化即感冒，平均1-2个月患感冒一次。每天睡前口服本发明的胶囊2粒(0.5g/粒)，服用2个月后，免疫力提高，能抵抗天气的变化，患感冒次数明显减少。
例2：张某，男，65岁，早期表征现象为：骨质疏松引发关节炎，血管硬化引发轻微中风，记忆力下降，倦怠乏力，烦躁易怒，性功能减退，属于典型的衰老症状。服用本发明的抗衰老保健品进行保健治疗，早晚各口服片剂2片(0.4g/片)，3个月后，以上表征现象中有些减轻，有些表征症状消失，体力及精神明显好转，性功能提高，无任何不适，有些的抑制和缓解了衰老症状。
例3：李某某，女，57岁，早期表现为：情绪波动、失眠、记忆力减退、月经紊乱、性欲减退、乳房萎缩、皮肤变得粗糙晦暗、弹性减退、毛孔粗大、皱纹加深，典型的衰老症状。每天睡前热水冲服本发明的颗粒剂1袋(1g/袋)，服用2个月后，睡眠质量好，睡眠深，记忆力增加、月经正常、皮肤红润，有光泽，皮肤有弹性，皱纹减少。
Claims (3)
1.一种具有抗衰老功能的保健品，其特征在于，它是由以下重量份的原料组成：胶原蛋白300-500份、维生素C 80-150份、维生素E 10-40份、玫瑰花提取物8-16份。
2.根据权利要求1所述的抗衰老功能的保健品，其特征在于，它是由以下重量份的原料组成：胶原蛋白400份、维生素C 100份、维生素E 20份、玫瑰花提取物10份。
3.根据权利要求1所述的抗衰老功能的保健品，其特征在于，所述各原料按量称取后，按照常规方法制成胶囊剂、片剂、颗粒剂、粉剂或丸剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610485583.0A CN106107979A (zh) | 2016-06-28 | 2016-06-28 | 一种具有抗衰老功能的保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610485583.0A CN106107979A (zh) | 2016-06-28 | 2016-06-28 | 一种具有抗衰老功能的保健品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106107979A true CN106107979A (zh) | 2016-11-16 |
Family
ID=57265878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610485583.0A Pending CN106107979A (zh) | 2016-06-28 | 2016-06-28 | 一种具有抗衰老功能的保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106107979A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110236035A (zh) * | 2019-07-12 | 2019-09-17 | 早康枸杞股份有限公司 | 一种枸杞山楂保健原浆及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160667A (zh) * | 2011-01-26 | 2011-08-24 | 王雄 | 天然有机可提高女性睡眠质量的饮料 |
| CN103372201A (zh) * | 2012-04-23 | 2013-10-30 | 王铁良 | 硬胶囊剂配方及其生产方法 |
| CN104770738A (zh) * | 2015-04-15 | 2015-07-15 | 威海御膳坊生物科技有限公司 | 一种羊胎盘冻干粉复合制剂 |
| CN105614718A (zh) * | 2015-12-25 | 2016-06-01 | 绍兴文理学院 | 一种适用于糖尿病人的乌发美容养颜药膳及其制备方法 |
-
2016
- 2016-06-28 CN CN201610485583.0A patent/CN106107979A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102160667A (zh) * | 2011-01-26 | 2011-08-24 | 王雄 | 天然有机可提高女性睡眠质量的饮料 |
| CN103372201A (zh) * | 2012-04-23 | 2013-10-30 | 王铁良 | 硬胶囊剂配方及其生产方法 |
| CN104770738A (zh) * | 2015-04-15 | 2015-07-15 | 威海御膳坊生物科技有限公司 | 一种羊胎盘冻干粉复合制剂 |
| CN105614718A (zh) * | 2015-12-25 | 2016-06-01 | 绍兴文理学院 | 一种适用于糖尿病人的乌发美容养颜药膳及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 江省蓉等: "《图解保健食品全书》", 31 May 2015, 湖南科学出版社 * |
| 艾铁民: "《中国植物志（第四卷）》", 31 August 2015, 北京大学医学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110236035A (zh) * | 2019-07-12 | 2019-09-17 | 早康枸杞股份有限公司 | 一种枸杞山楂保健原浆及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
| CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
| CN101438843A (zh) | 果蔬豆奶系列饮料 | |
| KR20160026916A (ko) | 다기능성 조성물 및 이의 제조 방법과 용도 | |
| KR20210060717A (ko) | 피로회복을 위한 경구용 수액분말 조성물 및 이의 제조방법 | |
| CN105410930A (zh) | 一种具有减肥瘦身、均衡营养功能的保健品及其制备方法 | |
| CN102106578B (zh) | 增强机体免疫力，提升男性性功能的饮料 | |
| KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
| CN106107979A (zh) | 一种具有抗衰老功能的保健品 | |
| KR20210104952A (ko) | 배변유도 및 다이어트용 건강기능식품 | |
| CN103815503A (zh) | 一种枸杞子胶原蛋白美容保健饮料 | |
| CN106880054A (zh) | 一种预防和治疗肌肉萎缩症的保健食品及其制备方法 | |
| CN103549083A (zh) | 一种保健养生茶 | |
| KR20140065924A (ko) | 양파껍질 분말을 주제로 하는 건강 보조식품 | |
| KR20210085684A (ko) | 미백 및 주름개선을 위한 피부미용 건강식품 조성물 | |
| CN110236035A (zh) | 一种枸杞山楂保健原浆及其应用 | |
| KR101485261B1 (ko) | 율무를 포함하는 변비개선 및 피로회복용 환제 조성물 및 그 제조 방법 | |
| CN110013028A (zh) | 一种食疗养生保健产品 | |
| Brewer | The Essential Guide to Vitamins, Minerals and Herbal Supplements | |
| KR100441308B1 (ko) | 다이어트 인삼복합음료 및 그 제조방법 | |
| RU2176514C2 (ru) | Композиция, обладающая общеукрепляющим и стимулирующим действием (варианты) | |
| JP2017042144A (ja) | 経口組成物 | |
| KR20050080502A (ko) | 녹차, 다시마, 연잎, 대나무잎, 뽕잎, 감잎, 솔잎의성분이 함유된 저염도 기능성 소금의 제조방법 | |
| Dąbrowska | Dr. Ewa Dąbrowska's Diet®: The phenomenon of the self-healing body. How does the vegetable and fruit fasting work? | |
| JP2003079340A (ja) | 体質改善健康食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170519 Address after: Qing Ping Road Qingpu District Xujing town Shanghai City Luzhou 201700 No. 2008 floor 10 room 1025 Applicant after: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. Address before: 200030 Shanghai city Xuhui District Yunjin Road No. 500 Green Exchange Center B building 17 floor Applicant before: Zhang Biao |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190117 Address after: Room 503, 5th floor, Daye Plaza, Jingheng, 2008, Shanghai Qingpu District, Shanghai Applicant after: Shanghai Yuanding Biotechnology Co., Ltd. Address before: Room 1025, 10th floor, 2008 Luqingping Road, Xujing Town, Qingpu District, Shanghai Applicant before: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |